USPTO serial 79448562
Reviewed by CopyMark Law Group
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia. | ACTIVE | — |
| 010 | Devices for introducing pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS), and parts and fittings therefor; devices for introducing pharmaceutical preparations, namely for treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia, and parts and fittings therefor. | ACTIVE | — |
| 044 | Medical and pharmaceutical services, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical advice, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical services, namely in relation to treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia. | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 24, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 9, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 9, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 26, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 25, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 23, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 23, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |